Bio-Rad Laboratories, Inc. Class A Common Stock vs Lululemon Athletica Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $299.9 (market cap $8.04B), while Lululemon Athletica Inc trades at $119.48 (market cap $13.32B). The key difference: Lululemon Athletica Inc is the larger of the two by market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Lululemon Athletica Inc nearer its low. Which is the better fit depends on your goals.
| BIO | LULU | |
|---|---|---|
Market Cap | $8.04B | $13.32B |
Sector | Health | Consumer Cyclical |
52-Week High | $339.75 | $233.31 |
52-Week Low | $241.71 | $105.43 |
Enterprise Value | $7.85B | $13.94B |
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Lululemon (LULU) trades at $120.30, up 0.87% today, showing resilience amid a challenging year. The stock has beaten earnings estimates for three consecutive quarters, with Q2 2026 results pending. Fundamentals remain strong with a 17.13% net margin and 32.03% ROE in 2025, though revenue growth is moderating. Technical indicators signal a bullish bias, with the current price near pivot point support at $121. Recent news highlights board stability after a proxy settlement but also ongoing brand controversies.
The outlook is cautiously optimistic. Valuation appears attractive with a P/E of 9.74, below sector averages, and a consensus price target of $130.53 implies upside. Key risks include North American sales weakness, intense competition, and potential brand damage from recent controversies. Earnings execution and international expansion are critical for a sustained recovery.
Trailing returns across standard periods
Latest headlines on both assets
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →Lululemon Athletica Inc. designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. Lululemon offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. The company also sells fitness accessories, such as bags, yoga mats, and equipment. Lululemon sells its products through more than 600 company-owned stores in 18 countries, e-commerce, outlets, and wholesale accounts. The company was founded in 1998 and is based in Vancouver, Canada.
Read more on LULU →